text: <unk>  is an antineoplastic agent that is FDA approved for the treatment of patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.   Common adverse reactions include cough, constipation, dysgeusia, peripheral edema, back pain, dizziness, headache, urinary tract infection, dyspnea, and rash. leukopenia, stomatitis, peripheral neuropathy, pyrexia, hypomagnesemia, hyperglycemia, anxiety, depression, insomnia, dysuria, urinary incontinence,  dry skin/ eczema, pruritis, hypertension, venous thrombosis (including pulmonary embolism), and hot flush.
option_0: Olaparib
option_1: Panobinostat
option_2: Floxuridine
option_3: Idoxuridine
option_4: Decitabine
option_5: Ibacitabine
option_6: Trifluridine
option_7: Axitinib